RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
19 October 2023 - 12:00AM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based therapeutics company focused on discovering,
developing and commercializing oral small molecule therapies for
patients with significant unmet needs in inflammatory diseases and
oncology, today announced it will present two posters on FLX475,
its oncology drug candidate, at the Society for Immunotherapy of
Cancer 2023 Annual Meeting taking place November 3-5, 2023 in San
Diego, CA.
Poster presentation details:
Title: |
Phase 2 safety
and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon)plus
pembrolizumab in subjects with non-small cell lung cancer not
previouslytreated with checkpoint inhibitor |
Abstract
Number: |
629-C |
Date &
Time: |
Friday, November 3, 2023; 9:00 a.m. – 7:00 p.m. PT |
Location: |
Exhibit Hall B – San Diego Convention Center |
|
|
Title: |
Biological activity of FLX475, an oral CCR4 antagonist, as
monotherapy and incombination with pembrolizumab in advanced
cancer |
Abstract
Number: |
704 |
Date &
Time: |
Saturday, November 4, 2023; 9:00 a.m. – 8:30 p.m. PT |
Location: |
Exhibit Halls A and B1 – San Diego Convention Center |
|
|
The full abstracts will be released to the public on Tuesday,
October 31, 2023 at 9:00 a.m. ET in a Journal for ImmunoTherapy of
Cancer (JITC) supplement.
About RAPT Therapeutics, Inc.RAPT Therapeutics
is a clinical-stage, immunology-based therapeutics company focused
on discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in inflammatory
diseases and oncology. Utilizing its proprietary discovery and
development engine, the Company is developing highly selective
small molecules designed to modulate the critical immune drivers
underlying these diseases. RAPT has discovered and advanced two
unique drug candidates, RPT193 and FLX475, each targeting C-C motif
chemokine receptor 4 (CCR4), for the treatment of inflammation and
cancer, respectively. The Company is also pursuing a range of
targets that are in the discovery stage of development.
Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2024 to May 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From May 2023 to May 2024